Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance mutations against HCV protease inhibitors and antiviral drug design.

Current pharmaceutical design - 1 Jan 2014

Shang Luqing, Lin Kai, Yin Zheng

Abstract excerpt

The treatment for hepatitis C virus (HCV) infection has been significantly improved with the approval of the first two HCV NS3/4A protease inhibitors, telaprevir (Incivek) and boceprevir (Victrelis). These two direct acting antivirals (DAAs) are used clinically in combination with pegylated interferon-alpha (PEG-IFNα) and ribavirin (RBV). The sustained virologic response (SVR) rates are increased to ~70% and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Design
Share to Drug Resistance, Multiple, Viral
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Conformation

Share to Molecular Targeted Therapy

Share to Serine Endopeptidases

Share to Serine Proteinase Inhibitors

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 23688081
DOI: 10.2174/13816128113199990008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance mutations against HCV protease inhibitors and antiviral drug design.PMID 23688081Read ↗

The role of resistance in HCV treatment.Semantic proximity Read ↗

Hepatitis C virus NS5A inhibitors and drug resistance mutations.Semantic proximity Read ↗

The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease InhibitorsSemantic proximity Read ↗

Hepatitis C virus resistance to protease inhibitors.Semantic proximity Read ↗

Analysis of Naturally Occurring Resistance-Associated Variants to NS3/4A Protein Inhibitors, NS5A Protein Inhibitors, and NS5B Polymerase Inhibitors in Patients With Chronic Hepatitis C.Semantic proximity Read ↗

Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018.Semantic proximity Read ↗

Hepatitis C RNA-dependent RNA polymerase inhibitors: a review of structure-activity and resistance relationships; different scaffolds and mutations.Semantic proximity Read ↗

Directly acting antivirals against hepatitis C virus: mechanisms of action and impact of resistant associated variants.Semantic proximity Read ↗

Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus InfectionsSemantic proximity Read ↗

The emerging field of HCV drug resistanceSemantic proximity Read ↗

Exploring the Drug Resistance of HCV Protease.Semantic proximity Read ↗

Virologic Tools for HCV Drug Resistance TestingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.